Molecular docking studies and structural&electronic analysis of gefarnate
Özet
This study focused on the structural/electronic features of an anti-ulcer agent, gefarnate. The molecular geometry of the compound was calculated using Gaussian 09 W software and the structure was optimized using the DFT/B3LYP method with the 6–31++G(d,p) basis set ground state. Also, in silico studies like molecular docking studies and ADME/T estimation were carried out using web-based tools and software. The protein used in these calculations is the crystal structure of the 3U6J, VEGFR2 kinase domain in complex with a pyrazolone inhibitor. The binding energy for the gefarnate molecule-VEGFR2 kinase complex has been computed as −8.6 kcal/mol. The compound showed no toxicity properties including cytotoxic, mutagenic, carcinogenic, or immunogenic. © 2023 Indian Chemical Society
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Çağlar Yavuz, Sevtap | |
| dc.date.accessioned | 2026-10-18T20:27:11.196399313Z | |
| dc.date.available | 2026-10-18T20:27:11.196399313Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | This study focused on the structural/electronic features of an anti-ulcer agent, gefarnate. The molecular geometry of the compound was calculated using Gaussian 09 W software and the structure was optimized using the DFT/B3LYP method with the 6–31++G(d,p) basis set ground state. Also, in silico studies like molecular docking studies and ADME/T estimation were carried out using web-based tools and software. The protein used in these calculations is the crystal structure of the 3U6J, VEGFR2 kinase domain in complex with a pyrazolone inhibitor. The binding energy for the gefarnate molecule-VEGFR2 kinase complex has been computed as −8.6 kcal/mol. The compound showed no toxicity properties including cytotoxic, mutagenic, carcinogenic, or immunogenic. © 2023 Indian Chemical Society | |
| dc.identifier.doi | 10.1016/j.jics.2023.100971 | |
| dc.identifier.issn | 0019-4522 | |
| dc.identifier.issue | 4 | |
| dc.identifier.scopus | 2-s2.0-85150387927 | |
| dc.identifier.startpage | 100971 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/12267 | |
| dc.identifier.volume | 100 | |
| dc.identifier.wos | WOS:000961653100001 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier B.V. | |
| dc.relation.ispartof | Journal of the Indian Chemical Society | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | ADMET | |
| dc.subject | DFT | |
| dc.subject | Gefarnate | |
| dc.subject | Molecular docking | |
| dc.subject | acetylsalicylic acid | |
| dc.subject | celecoxib | |
| dc.subject | cyclooxygenase 2 inhibitor | |
| dc.subject | cytochrome P450 1A2 inhibitor | |
| dc.subject | cytochrome P450 2C19 inhibitor | |
| dc.subject | cytochrome P450 2C9 inhibitor | |
| dc.subject | cytochrome P450 2D6 inhibitor | |
| dc.subject | diclofenac | |
| dc.subject | diflunisal | |
| dc.subject | etodolac | |
| dc.subject | etoricoxib | |
| dc.subject | fenoprofen calcium | |
| dc.subject | ibuprofen | |
| dc.subject | indometacin | |
| dc.subject | ketoprofen | |
| dc.subject | lumiracoxib | |
| dc.subject | magnesium salicylate | |
| dc.subject | mefenamic acid | |
| dc.subject | naproxen | |
| dc.subject | phosphotransferase | |
| dc.subject | piroxicam | |
| dc.subject | pyrazolone | |
| dc.subject | salsalate | |
| dc.subject | vasculotropin receptor 2 | |
| dc.subject | Article | |
| dc.subject | calculation | |
| dc.title | Molecular docking studies and structural&electronic analysis of gefarnate | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 1 | |
| rdl.citation.wos | 0 | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
